Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Launches the Sius™ Single-use TFF Skid

Published: Friday, February 15, 2013
Last Updated: Friday, February 15, 2013
Bookmark and Share
Sius™ TFF skid to be showcased at the disposable solutions for biomanufacturing tradeshow in Brussels on February 19-20, 2013.

Novasep has announced the launch of its Sius™ single-use tangential flow filtration (TFF) skid.

The TFF skid completes the Novasep proprietary, single-use TFF solution for pre-clinical to clinical cGMP biomanufacturing.

The new skid is the first on the market to offer a 100 per cent single-use TFF solution.

The Sius TFF skid is comprised of an automated bench top unit with a fully disposable flowpath and is extremely compact. It is capable of lab to pilot scale TFF operations.

Eliminating the risk of cross contamination, the unit widens the market for disposable TFF solutions, accommodating surface areas from 0.1 square meters to 2 square meters for microfiltration and ultrafiltration/diafiltration (UF/DF) applications.

Novasep has achieved a 73 to 80 per cent reduction in consumable price to USD 800/ square meter, by designing the TangenX® Sius Single-use TFF cassettes to be more cost effective. This compares to USD 3000/ square meter to USD 4000/ square meter for competing products.

The long term drive by the biopharmaceutical industry to reduce costs, including the costly effort of cleaning equipment and validation, makes it increasingly reliant on disposable technologies.

These offer numerous benefits over traditional reusable technologies. One of the most important of these is a time saving of 50 to 70 per cent using Sius technology over traditional reusable TFF technologies.

The Novasep Sius TFF skid’s flowpath can be combined with TangenX Sius TFF cassettes and filter plate inserts with the option of a feed bag, to provide a complete single-use TFF solution from a single supplier for pre-clinical to clinical cGMP biomanufacturing. It is also one of the only solutions to enable cGMP validated integrity tests.

“As the biopharmaceutical market continues to evolve, demand continues to rise for more cost-effective and comprehensive solutions,” said Alain Lamproye, president of Novasep’s Biopharma business unit.

Lamproye continued, “Novasep has reacted to this by concentrating on continuing to increase its product and service portfolio in the downstream processing marketplace and we will continue to do so. By launching Sius TFF Skid, Novasep now offers the first 100 per cent single-use TFF solution on the market whilst remaining very cost effective. We are also developing a larger scale Sius TFF skid to cover commercial scale applications.”

Novasep will be presenting the Sius TFF skid at the Disposable Solutions for Biomanufacturing tradeshow in Brussels on February 19-20, 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!